Skip to main content

Advertisement

SpringerLink
Log in

ASO Visual Abstract: Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients

  • ASO Visual Abstract
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Funding

This work was supported by Sysmex Corporation. The funding source had no involvement in study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the article for publication. A patent application has been filed relating to this work (WO2016/136684).

Author information

Authors and Affiliations

  1. Department of Surgery, National Defense Medical College, Tokorozawa, Saitama, Japan

    Eiji Shinto MD & Kazuo Hase MD

  2. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Eiji Oki MD

  3. Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan

    Mototsugu Shimokawa PhD

  4. Department of Surgery, Division of Colorectal Surgery, Tokyo Women’s Medical University, Tokyo, Japan

    Shigeki Yamaguchi MD

  5. Medical Innovation Promotion Center, Tokyo Medical and Dental University, Tokyo, Japan

    Megumi Ishiguro MD

  6. Department of Surgery, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan

    Seiji Hasegawa MD

  7. Department of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan

    Yasumasa Takii MD

  8. Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

    Hideyuki Ishida MD

  9. Department of Gastroenterological Surgery, Clinical Research Center, Cancer Research Division, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

    Tetsuya Kusumoto MD

  10. Department of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

    Masaru Morita MD

  11. Cancer Treatment Center, Toyonaka Municipal Hospital, Toyonaka, Japan

    Naohiro Tomita MD

  12. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan

    Manabu Shiozawa MD

  13. Coloproctology Center, Takano Hospital, Kumamoto, Japan

    Masafumi Tanaka MD

  14. Department of Colorectal Surgery, Tochigi Cancer Center, Utsunomiya, Japan

    Heita Ozawa MD

  15. Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan

    Yojiro Hashiguchi MD

  16. Department of Surgery, Tohoku University Hospital, Sendai, Japan

    Shinobu Ohnuma MD

  17. LS Business, Sysmex Corporation, Kobe, Japan

    Sachiyo Tada PhD, Tomoko Matsushima PhD & Keisuke Yamagishi PhD

Authors
  1. Eiji Shinto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eiji Oki MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mototsugu Shimokawa PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shigeki Yamaguchi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Megumi Ishiguro MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seiji Hasegawa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasumasa Takii MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hideyuki Ishida MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tetsuya Kusumoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masaru Morita MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Naohiro Tomita MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Manabu Shiozawa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Masafumi Tanaka MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Heita Ozawa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yojiro Hashiguchi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Shinobu Ohnuma MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Sachiyo Tada PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Tomoko Matsushima PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Keisuke Yamagishi PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Kazuo Hase MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eiji Shinto MD.

Ethics declarations

Disclosure

E.O. is on the speakers’ bureau for Bayer, Chugai Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, and Bristol-Myers; MS has a consulting/advisory role for Sysmex; S.Y. is on the speakers’ bureau for Chugai Pharmaceutical, Covidien, Eli Lilly, Merck Serono, Johnson & Johnson, and Taiho Pharmaceutical; N.T. received research funding from Chugai Pharmaceutical and Taiho Pharmaceutical; Y.H. received honoraria from Bayer, Chugai Pharmaceutical, Kaken Pharmaceutical, Merck Serono, Sanofi, Taiho Pharmaceutical, and Takeda Pharmaceutical, as well as research funding from Chugai Pharmaceutical, Kaken Pharmaceutical, Merck Serono, Sanofi, Taiho Pharmaceutical, and Takeda Pharmaceutical; S.T., T.M., and K.Y. are employed by Sysmex and have stock/other ownership in Sysmex; and E.S., M.I., S.H., Y.T., H.I., K.T., M.M., MS, M.T., H.O., S.O., and K.H. have no relationship to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shinto, E., Oki, E., Shimokawa, M. et al. ASO Visual Abstract: Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients. Ann Surg Oncol 30, 5250–5251 (2023). https://doi.org/10.1245/s10434-023-13684-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-023-13684-0

Search

Navigation